We are committed to leading the development of first-in-class, highly-selective, and potent small molecule inhibitors of nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme highly expressed in select tissue (e.g., adipocytes, hepatocytes, muscle), where it plays a critical role in regulating energy metabolism and epigenetic pathways.
Substantial evidence supports enhanced NNMT expression and activity linking to a number of chronic diseases; high NNMT expression and activity in white adipose tissue, as observed in obesity, strongly triggers adiposity-induced insulin resistance and related metabolic syndrome (Type 2 Diabetes). Similarly, several skeletal muscle disorders including muscular dystrophies (e.g., Duchene Muscular Dystrophy) and age-related muscle degeneration (e.g., sarcopenia) are characterized by a surge in NNMT expression and subsequently reduced cellular NAD+ levels.
We have developed a series of selective small molecule NNMT inhibitors with attractive drug-like properties, and are accelerating our efforts to transition our novel lead drug candidates through preclinical development and to Phase I trials.
Cutting edge science around cellular metabolism and epigenetics anchors Ridgeline's innovative first-in-class drugs.